Related Experiment Video
Updated: Aug 21, 2026

CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum
Published on: September 18, 2018
Point mutations and pyrimethamine resistance in Plasmodium falciparum
1Department of Biochemistry and Applied Molecular Biology, University of Manchester Institute of Science and Technology, Manchester, M601 QD, UK.
Abstract:
Pyrimethamine was first introduced as a prophylactic antimalarial in 1952, with the advantages of low toxicity and freedom from side-effects. As early as the mid-1950s, parasite resistance to this compound had been reported from several areas, and it has since become widespread on all continents where malaria is found. Although it is still used for the suppression of infection, predominantly in conjunction with sulphone or sulphonamide drugs, even these combinations are now useless in many areas. Pyrimethamine resistance is less important globally than resistance to the major curative drug chloroquine, but it has long tantalized molecular parasitologists because pyrimethamine belongs to the only class of antimalarials for which the target molecule is unambiguously known.
More Related Videos
10:22Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum
Published on: December 4, 2015
09:13Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases
Published on: November 22, 2024
Related Concept Videos
Malaria
Point and Frameshift Mutations
Mutations
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Genome Copying Errors
Spontaneous and Induced Mutations